PHAT
Income statement / Annual
Last year (2024), Phathom Pharmaceuticals, Inc.'s total revenue was $55.25 M,
an increase of 8,001.47% from the previous year.
In 2024, Phathom Pharmaceuticals, Inc.'s net income was -$334.33 M.
See Phathom Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$55.25 M |
$682.00 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$7.97 M
|
$167.00 K
|
$620.00 K
|
$521.00 K
|
$300.00 K
|
$8.00 K
|
$0.00
|
| Gross Profit |
$47.28 M
|
$515.00 K
|
-$620.00 K
|
-$521.00 K
|
-$300.00 K
|
-$8.00 K
|
$0.00
|
| Gross Profit Ratio |
0.86
|
0.76
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$34.08 M
|
$49.90 M
|
$71.44 M
|
$72.34 M
|
$98.15 M
|
$99.27 M
|
$20.00 K
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$6.94 M
|
$1.21 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$290.66 M
|
$117.93 M
|
$100.38 M
|
$62.22 M
|
$27.22 M
|
$6.94 M
|
$1.21 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$324.75 M
|
$167.83 M
|
$171.82 M
|
$134.56 M
|
$125.37 M
|
$106.22 M
|
$1.23 M
|
| Cost And Expenses |
$332.72 M
|
$167.99 M
|
$172.44 M
|
$135.08 M
|
$125.67 M
|
$106.22 M
|
$1.23 M
|
| Interest Income |
$15.16 M
|
$7.88 M
|
$2.13 M
|
$41.00 K
|
$1.09 M
|
$1.09 M
|
$0.00
|
| Interest Expense |
$72.01 M
|
$41.97 M
|
$27.31 M
|
$6.79 M
|
$4.58 M
|
$4.18 M
|
$13.00 K
|
| Depreciation & Amortization |
$795.00 K
|
$575.00 K
|
$620.00 K
|
$521.00 K
|
$300.00 K
|
$8.00 K
|
$1.23 M
|
| EBITDA |
-$261.52 M |
-$159.05 M |
-$169.80 M |
-$136.57 M |
-$124.19 M |
-$250.95 M |
-$50.00 K |
| EBITDA Ratio |
-4.73
|
-233.21
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-5.02
|
-245.33
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$56.86 M
|
-$34.28 M
|
-$25.28 M
|
-$8.80 M
|
-$3.40 M
|
-$148.92 M
|
-$63.00 K
|
| Income Before Tax |
-$334.33 M
|
-$201.59 M
|
-$197.72 M
|
-$143.88 M
|
-$129.07 M
|
-$255.13 M
|
-$1.29 M
|
| Income Before Tax Ratio |
-6.05
|
-295.59
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$13.00 K
|
| Net Income |
-$334.33 M
|
-$201.59 M
|
-$197.72 M
|
-$143.88 M
|
-$129.07 M
|
-$209.74 M
|
-$1.29 M
|
| Net Income Ratio |
-6.05
|
-295.59
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-5.29 |
-3.93 |
-5.7 |
-4 |
-4.01 |
-8.48 |
-0.15 |
| EPS Diluted |
-5.29 |
-3.93 |
-5.7 |
-4 |
-4.01 |
-8.48 |
-0.15 |
| Weighted Average Shares Out |
$63.18 M
|
$51.29 M
|
$39.12 M
|
$37.00 M
|
$33.23 M
|
$24.73 M
|
$8.58 M
|
| Weighted Average Shares Out Diluted |
$63.18 M
|
$51.29 M
|
$39.12 M
|
$37.00 M
|
$33.23 M
|
$24.73 M
|
$8.58 M
|
| Link |
|
|
|
|
|
|
|
